[Dehydroepiandrosterone sulfate and insulin of prepubertal girls born small for gestational age]

You-zhi Jiang1, Min Zhu, Feng Xiong

  • 1Department of Pediatric Endocrinology, The Affiliated Children's Hospital of Chongqing University of Medical Sciences, Chongqing 400014, China. youzhijiang74@yahoo.com.cn

Insights

Girls born small for gestational age (SGA) exhibit earlier adrenarche and adrenal hyperandrogenism. While hyperinsulinism is present, insulin resistance was not detected in these prepubertal girls.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Adolescent Health

Context:

  • Low birth weight, specifically being small for gestational age (SGA), is a potential risk factor for later health issues.
  • Understanding the endocrine development in SGA children is crucial for early intervention and management.
  • Prepubertal endocrine changes, including adrenarche, can predict future metabolic and hormonal imbalances.

Purpose:

  • To investigate the association between low birth weight (SGA) and the risk of premature adrenarche, adrenal hyperandrogenism, hyperinsulinism, and insulin resistance in prepubertal girls.
  • To determine the onset of adrenarche in SGA infants compared to normal birth weight girls.

Summary:

  • This study compared 39 prepubertal SGA girls with 42 appropriate for gestational age (AGA) girls.
  • SGA girls showed significantly lower birth weight, height, and weight, but similar BMI and glucose levels compared to AGA girls.
  • Fasting insulin and dehydroepiandrosterone sulfate (DHEAS) were significantly higher in SGA girls, indicating hyperinsulinism and adrenal hyperandrogenism. Adrenarche tended to occur earlier in SGA girls, but no insulin resistance was observed.

Impact:

  • The findings suggest that SGA is associated with earlier adrenarche and adrenal hyperandrogenism in prepubertal girls.
  • Early adrenarche in SGA girls may signal a need for closer monitoring for potential metabolic disturbances.
  • This research contributes to understanding the long-term endocrine consequences of fetal growth restriction.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...